An observational study in ALL, Childhood and Acute Lymphoblastic Leukemia, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by St. Jude Children's Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 8th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 13 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 57th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
St. Jude Children's Research Hospital · Sites in United States
Ages 18+
St. Jude Children's Research Hospital · Sites in United States
Ages 20–50
By country, each count listing its studies:
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 8 · Phase 4 2
First in 1993; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 107 across 401 observational studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 42 across the 57 interventional studies, 165 across the 13 observational. Of the 44 that completed or were terminated, 17 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
6 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747910St. Jude Children's Research HospitalAssessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma | 2026-12 |
| NCT04195347St. Jude Children's Research HospitalStudy of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | 2027-01 |
| NCT05763290St. Jude Children's Research HospitalChildhood Cancer Survivors' Affective Response to Exercise | 2027-02 |
| NCT06819475St. Jude Children's Research HospitalImaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors | 2027-07 |
| NCT04881240St. Jude Children's Research HospitalStudy of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the feasibility of administering the Personalized Single-Category Implicit Association Test (PSC-IAT) to young adult survivors of childhood cancer.
Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
Researchers at St. Jude Children's Research Hospital want to learn about the measurement of implicit association bias towards or against exercise in childhood cancer survivors. Additionally, researchers want to learn more about the physical and emotional experience of exercise from our survivors.
The plan for this study is to administer single category implicit association tests (PSC-IAT's) to participants during on campus SJLIFE testing and use this data to determine the feasibility of this tool's use in survivors of childhood cancer without cognitive impairment. This study will also administer the Behavioral Regulations in Exercise Questionnaire (BREQ-2)37 to participants as a construct validity check to the PSC-IAT.
The procedures include PSC-IAT and BREQ-2 tests (before and after strenuous exercise as part of the SJLIFE protocol) and a qualitative interview. These will be in addition to standard components of the SJLIFE on-campus visit.
The study population will include survivors from the SJLIFE cohort from the ALL diagnostic group (treated without cranial radiation therapy (CRT). This group was chosen because of the prevalence of ALL in childhood cancer diagnoses, and to attempt to prevent potential difficulties with the cognitive task due to cognitive impairment from CRT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.
Implicit Association Bias Testing
Participants' implicit associations with exercise will be measured using the Personalized Single-Category Implicit Association test (PSC-IAT).
Time frame: Before and after Cardiovascular Stress Testing at Baseline
Behavioral Regulation of Exercise Questionnaire (BREQ-2):
The Behavioral Regulation of Exercise Questionnaire (BREQ-2) will be administered once to participants in this study to assess trait-level affective motivation.
Time frame: Before and after Cardiovascular Stress Testing at Baseline
Started Mar 2023 (actual). Primary completion is estimated for Feb 2027, 47 months after the start.
Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 47 months is close to that.
Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
St. Jude Children's Research Hospital →